As previously reported, Cowen analyst Steve Scala upgraded AstraZeneca to Outperform from Market Perform, stating that the 5% stock decline on news of the company’s partnership with Daiichi Sankyo for trastuzumab deruxtecan, which he calls a “promising” breast cancer drug, offers a compelling entry point. Key opinion leading doctors he speaks with anticipate use of trastuzumab deruxtecan in many patients with metastatic HER2+ disease, while low HER2+ “shows promise but requires more data,” said Scala. Meanwhile, Imfinzi, Tagrisso and Lynparza all have “big potential” and Roxadustat “offers upside,” the analyst tells investors. He raised his price target on AstraZeneca shares to $48 from $42.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.